医学
入射(几何)
儿科
流行病学
预防性抗生素
B组
比率
公共卫生
疾病
抗生素
内科学
置信区间
物理
微生物学
护理部
光学
生物
作者
Verna Björklund,Harri Saxén,Olof Hertting,Emma Louise Malchau Carlsen,Steen Hoffmann,Stellan Håkansson,Valtýr Thors,Ásgeir Haraldsson,Anne Karin Brigtsen,Henrik Døllner,Heikki Huhtamäki,Tytti Pokka,Tarja Ruuska
出处
期刊:Eurosurveillance
[European Centre for Disease Control and Prevention (ECDC)]
日期:2024-01-18
卷期号:29 (3)
被引量:1
标识
DOI:10.2807/1560-7917.es.2024.29.3.2300193
摘要
BackgroundNeonatal early-onset disease caused by group B Streptococcus (GBS) is a leading cause of infant morbidity. Intrapartum antibiotic prophylaxis (IAP) is effective in preventing early-onset GBS disease, but there is no agreement on the optimal strategy for identifying the pregnant women requiring this treatment, and both risk-based prophylaxis (RBP) and GBS screening-based prophylaxis (SBP) are used.AimThe aim of this study was to evaluate the effect of SBP as a public health intervention on the epidemiology of early-onset GBS infections.MethodsIn 2012, Finland started the universal SBP, while Denmark, Iceland, Norway and Sweden continued with RBP. We conducted an interrupted time series analysis taking 2012 as the intervention point to evaluate the impact of this intervention. The incidences of early- and late-onset GBS infections during Period I (1995-2011) and Period II (2012-2019) were collected from each national register, covering 6,605,564 live births.ResultsIn Finland, a reduction of 58% in the incidence of early-onset GBS disease, corresponding to an incidence rate ratio (IRR) of 0.42 (95% CI: 0.34-0.52), was observed after 2012. At the same time, the pooled IRR of other Nordic countries was 0.89 (95% CI: 0.80-1.0), specifically 0.89 (95% CI: 0.70-1.5) in Denmark, 0.34 (95% CI: 0.15-0.81) in Iceland, 0.72 (95% CI: 0.59-0.88) in Norway and 0.97 (95% CI: 0.85-1.1) in Sweden.ConclusionsIn this ecological study of five Nordic countries, early-onset GBS infections were approximately halved following introduction of the SBP approach as compared with RBP.
科研通智能强力驱动
Strongly Powered by AbleSci AI